AiLNP

AiRNA

AiTEM

AI驱动`药物递送`和`药物发现`

AI-Driven `Drug Delivery` and `Drug Discovery`

March 3, 2025 – METiS Pharmaceuticals, a clinical-stage, AI-driven biotechnology company specializing in innovative drug delivery technologies, today announced the appointment of Mark Herbert as Chief Business Officer (CBO), effective January 22, 2025. In this role, Mr. Herbert will lead global business development, build key partnerships, and explore new opportunities to support METiS’ growth and advance the commercialization of its drug delivery technologies.With over 20 years of experience in the biotechnology and pharmaceutical industries, Mr. Herbert has a proven track record in business development, commercialization, and strategic partnerships. Prior to joining METiS, he served as President of Arcturus Therapeutics, where he led strategic collaborations with Takeda Pharmaceutical and CureVac on platform and mRNA pipeline collaborations, generating over $2 billion in partnership value. He has also held key roles as Vice President of Business Development at Varda Space Industries, Chief Business Officer at Scientist.com, and served on the boards of multiple biotech companies. His extensive industry experience will be instrumental in METiS’ next phase of growth.“We are excited to welcome Mark Herbert to METiS,” said Dr. Chris Lai, Co-founder &amp; CEO of METiS Pharmaceuticals. “Mark is a highly experienced executive with a proven track record in driving business development and commercialization in the biotech space. His leadership will be instrumental in strengthening our partnerships and unlocking new growth opportunities as we enter this crucial phase.”&quot;Mark’s deep industry knowledge and global perspective will be invaluable as METiS accelerates its growth,&quot; said Dr. Hongmin Chen, Co-founder &amp; CRDO of METiS Pharmaceuticals. “His leadership will help enhance our business development efforts and foster partnerships that will bring our transformative drug delivery technologies to patients around the world.”&quot;Joining the talented team at METiS Pharmaceuticals is a tremendous honor,&quot; said Mark Herbert. &quot;I look forward to working closely with the team to advance our cutting-edge nucleic acid and drug delivery technologies, drive innovation, and expand our global partnerships. METiS is at the forefront of using AI to revolutionize drug delivery, and I’m thrilled to be part of this exciting journey.&quot;Over the years, METiS Pharmaceuticals has made significant progress in developing AI-driven LNP (lipid nanoparticle) delivery systems, achieving breakthroughs in targeted nano delivery for organs such as the liver, lungs, spleen, muscles, and central nervous system. These advancements demonstrate up to 20 times greater efficacy in liver cancer and lung tumors compared to industry standards. The company has also established strategic collaborations with over 20 leading global pharmaceutical and biotech companies.With Mark Herbert’s appointment, METiS is entering an exciting new chapter. Moving forward, it is committed to delivering transformative therapies to patients worldwide through its innovative delivery technologies. About METiS PharmaceuticalsFounded in 2020, <a name="_Hlk189663869">METiS Pharmaceuticals</a> is an AI-driven biotechnology company focused on drug delivery. Utilizing cutting-edge AI, machine learning, and quantitative modeling, METiS is redefining the drug delivery and drug development. The company is also pioneering programmable nucleic acid therapeutics and next-generation RNA delivery to address unmet medical needs, ultimately delivering transformative treatments to patients worldwide.

METiS Pharmaceuticals Appoints Mark Herbert as Chief Business Officer

METiS Pharmaceuticals, an innovative biotechnology company focusing on &quot;AI + drug delivery,&quot; announced the appointment of Dr. Wei Xu as Chief Scientific Officer. Dr. Xu will lead drug discovery and translational efforts to advance the mRNA-based therapeutics to the clinical stage. Dr. Xu will also work with the management team to establish high-value pipeline. <div class="media-wrap image-wrap align-center" style="text-align:center"><img class="media-wrap image-wrap align-center" src="https://oss.metispharmaceuticals.cn/b50b68383d77f0ef60c3dabf33342cd8.jpg" width="160.333px" height="213px" style="width:160.333px;height:213px"/></div>Dr. Wei Xu, CSO of METiS PharmaceuticalsDr. Xu possesses a strong academic and industrial background in various therapeutic fields including immunology, oncology, and cell therapy. He has held positions at multiple renowned companies, demonstrating a wealth of experience in research and development management.His academic career began at Leiden University Medical Center in the Netherlands, where he obtained his doctoral degree in Immunology in 2007. Subsequently, he joined the Baylor Institute for Immunology Research (Dallas) as a postdoctoral fellow. During his tenure at Roche Innovation Center Zurich (Switzerland), he has enabled 4 immunotherapy NMEs into clinical development. From 2018 to 2022, Dr. Xu served as Vice President and Head of New Drug Biology &amp; Translational Medicine at Innovent Biologics (Suzhou), where he built teams focused on novel biologics and translational medicine. He led the transformation of the company’s R&amp;D capabilities from “me-too” drugs to FIC and BIC drugs and even built cell therapy capability from scratch. He then returned to Switzerland and joined Numab Therapeutics as CSO, responsible for driving and executing the overall strategy in research and development pipeline, where he managed Drug discovery, Antibody discovery, CMC, and translational science teams.Dr. Xu Wei stated, &quot;I am extremely honored to join METiS Pharmaceuticals, a team full of vitality and innovative spirit. METiS has created the world&#x27;s first and best-in-class AI-driven drug delivery platform, tissue targeted lipid nanoparticles (LNP), opening up immense possibilities for the next generation of mRNA-encoded immunotherapy. I look forward to working with METiS’ Team to build innovative drug pipelines that are globally competitive.&quot;Hongming Chen, Sc.D., President and Head of R&amp;D warmly welcomes Dr. Xu &#x27;s joining, &quot;Dr. Xu is a world-class expert in drug discovery. His extensive experience and outstanding abilities will bring new impetus and vitality to our research and development efforts. We believe that under his leadership, our Drug Discovery Department will achieve greater breakthroughs, accelerating the development of the mRNA pipeline and developing more effective therapeutic drugs for patients worldwide.&quot;Dr. Chris Lai, co-founder &amp; CEO of METiS Pharmaceuticals, also expresses great anticipation for Dr. Xu&#x27;s joining, &quot;Dr. Xu&#x27;s joining infuses METiS with formidable research and development capabilities. As an innovative biotechnology company committed to advancing AI drug delivery and discovery, we have made significant progress in the field of small molecule drugs, with the fastest in Phase III clinical trials. Additionally, mRNA pipelines constitute our next strategic focus. We look forward to achieving greater achievements in drug development under Dr. Xu&#x27;s leadership at METiS.&quot; About METiS PharmaceuticalsMETiS Pharmaceuticals is an innovative biotechnology company driven by AI that harnesses targeted drug delivery and discovery technology to develop more effective drugs for patients. Through the integration of cutting-edge AI technology and traditional pharmaceutical R&amp;D, METiS aims to accelerate the R&amp;D of innovative drugs in a more efficient and precise way, while leveraging the core technology platforms to support the entire pharmaceutical ecosystem and lead industry innovation.METiS was founded and led by Hongming Chen, a member of the National Academy of Engineering; Dr. Chris Lai and Dr. Wenshou Wang, top scientists from MIT. On top of drug development experts from major pharmaceutical companies such as Regeneron, Amgen, and Novartis, we also host young talents in AI and computing.METiS has built 3 unique core-technology platforms: AiLNP (AI-driven RNA Delivery Design Platform), AiRNA (AI-driven mRNA design and synthesis platform), and AiTEM (AI-driven Small Molecule Formulation Design Platform). Based on these platforms, METiS has developed a portfolio of over 10 drugs, including small molecule and RNA drugs. Going forward, METiS will focus on RNA drugs and other innovative therapies with more challenging drug-delivery requirements to drive technological breakthroughs.

METiS Pharmaceuticals announced the appointment of Dr. Wei Xu as Chief Scientific Officer. Dr. Xu will lead drug discovery and translational efforts to advance the mRNA-based therapeutics to 

METiS Appoints Dr. Wei Xu as CSO to Accelerate mRNA Pipeline Development

Recently, the largest profiling of the global AI in the Drug Discovery industry made to date has been released in the form of an interactive IT-Platform and associated report by Deep Pharma Intelligence, a leading BioTech market research agency focused on sophisticated analytics, benchmarking and forecasting of emerging and frontier domains in the Pharmaceutical, BioTech and Healthcare industries.The AI in Drug Discovery platform features an interactive database of the Top 100 AI in Drug Discovery Experts, with information-rich profiles on the leading researchers, scientists, entrepreneurs and technologists committed to harnessing the potential of AI to tackle the complex challenges of drug discovery advancement.Dr. Hongming Chen, who is METiS Co-founder,President and Head of R&amp;D, ranked on the list ‘TOP 100 LEADERS of AI in Drug Discovery’.<div class="media-wrap image-wrap align-center" style="text-align:center"><img src="https://oss.metispharmaceuticals.cn/bc918d11436a88cafd649d6e726d62a3.png" width="685" height="405" style="width:685px;height:405px"/></div>Dr. Chen is a member of the National Academy of Engineering, a Fellow of the American Institute for Medical and Biological Engineering, a Fellow of the Controlled Release Society and a member of the Academy of Distinguished Chemical Engineers at the University of Texas at Austin. Dr. Chen holds a B.S. in Chemical Engineering from UT Austin and an M.S. and an Sc.D. in Chemical Engineering from Massachusetts Institute of Technology.Before joining METiS, Dr. Chen served as Chief Scientific Officer at Kala Pharmaceuticals, a biotech company she helped found in 2010. At Kala, she successfully translated a novel nanoparticle technology from bench to Phase III clinical trials and FDA approval, and helped to attract significant investments to the company, including an initial public offering in 2017. Prior to Kala, Dr. Chen helped start and build TransForm Pharmaceuticals, which was acquired by Johnson &amp; Johnson in 2005. She had also held various research positions at AstraZeneca and Merck.

剂泰医药联合创始人兼美国公司总裁、研发负责人陈红敏院士从全球众多创业者中脱颖而出，作为AI制药领域的企业家代表入选该100人名单。

Dr. Hongming Chen, who is METiS Co-founder,President and Head of R&D, ranked on the list ‘TOP 100 LEADERS AI in Drug Discovery’.

剂泰医药陈红敏院士入选“全球AI药物发现专家100人”

Dr. Hongming Chen ranked on the list ‘TOP 100 LEADERS of AI in Drug Discovery’

The 2023 World Artificial Intelligence Conference took place from July 6th to 8th at the Shanghai World Expo Center and the Shanghai World Expo Exhibition &amp; Convention Center. With the theme of &quot;Intelligent Connectivity Generating Future&quot;, this conference is co-sponsored by Shanghai Municipal Government, National Development and Reform Commission, Ministry of Industry and Information Technology, Ministry of Science and Technology, Cyberspace Administration of China, Chinese Academy of Sciences, Chinese Academy of Engineering, and China Association for Science and Technology. This conference is aimed at giving full play to its important role as “technology leader, application showcase, industry accelerator, and governance council”, bringing together profound wisdom, cutting-edge technologies, industrial trends, and human ecology in the global artificial intelligence field, and promoting the healthy and innovative development of artificial intelligence.On the morning of July 7th, as a representative of AI pharmaceutical companies, Dr. Chris Lai, the co-founder, and CEO of METiS Pharmaceuticals, participated upon invitation in the Financing and Investment sub-Forum of the 2023 World Artificial Intelligence Conference hosted by CICC and themed “Boundless Future, Booming of AIGC”. At the forum, he discussed the industry development and opportunities with the participants from the perspective of capital boosting the development of AI technology and shared his personal experiences and insights.<div class="media-wrap image-wrap"><img class="media-wrap image-wrap" src="https://oss.metispharmaceuticals.cn/de922bdb70d415b9841dc474220c7a20.png"/></div>The panel discussion was chaired by Zhang Qing, Managing Director of CICC Capital. Dr. Chris Lai, the co-founder and CEO of METiS Pharmaceuticals, John Qu, Global Senior Managing Partner of McKinsey &amp; Company, Han Wei, Chairman of AIForceTech, Ren Peng, Vice President at Perfect World and Head of Strategic Investment Department of, Nyx He, Senior Vice President and Partner at BrainCo, Wang Xiao, Partner at Unity Venture, and Zhang Suyang, Partner at Volcanics Venture, conducted a fruitful collision of ideas around the topic of“AI investment in the primary market at the dawn of a new wave”, actively offered advice and suggestions, and contributed their respective experiences and insights.<div class="media-wrap image-wrap"><img class="media-wrap image-wrap" src="https://oss.metispharmaceuticals.cn/9c62b8356adaf241e7897d474d3a758c.png"/></div>Dr. Lai introduced the key role of capital in the early development of AI companies, drawing on his experience as the founder of an AI-driven drug delivery and drug R&amp;D company. METiS Pharmaceuticals was founded by a group of MIT scientists and a member of the National Academy of Engineering (USA) in 2020. The founding of the company coincided with the outbreak of the COVID-19 pandemic, so all R&amp;D plans were put on hold. As a result, the founding team resolutely moved the core team from the United States to China, as well as their developing work of the platforms. Fortunately, METIS received adequate support from the Hangzhou Municipal Government in terms of start-up funds and laboratory placement, and therefore, quickly settled down in Hangzhou, China. Subsequently, the experimental data was quickly recognized by the capital market. For example, the delivery and transfection efficiency of nanocarriers designed by METiS is more than ten times higher than that of the industry giant Moderna. Meanwhile, METiS has addressed the delivery problems of the lungs, brain, tumors, immune organs, and muscles that are difficult for the industry to overcome. These impressive achievements obtained the support of leading funds, including Sequoia China, 5Y Capital, PICC Capital, and Lightspeed China. Thanks to the support of capital, METiS Pharmaceuticals has grown rapidly in the past three years and is now an innovative biotechnology company that has begun to take shape and focuses on AI-driven drug delivery and drug discovery.<div class="media-wrap image-wrap"><img class="media-wrap image-wrap" src="https://oss.metispharmaceuticals.cn/d4ea59defb2e554d181c1428fb4109b9.png"/></div>Dr. Lai is also very optimistic about the future of artificial intelligence technology. In recent years, he has witnessed the &quot;third drug revolution&quot; – the gene therapy drugs based on nucleic acid DNA and RNA codes, following the small molecule targeted drugs and antibody drugs. The mRNA vaccines developed by Moderna and BioNTech performed outstandingly during the COVID-19 pandemic, bringing nucleic acid gene drugs to the masses. The nano-delivery carrier LNP and RNA sequence have proved to be safer than expected, with unexpected drug effects, which has brought a wave of technological and financial benefits to the biopharmaceutical industry. METiS Pharmaceuticals has also joined the wave and quickly deployed the AI-driven nucleic acid delivery system design platform (AiLNP). Thanks to the contributions of the top scientists from MIT, AI technology platforms, and the capital market, METiS has created drug delivery and development capabilities that surpass the industry.Since the decoding of the human genome in 2000, the academic community has accumulated a large number of breakthroughs in molecular biology and genetic coding. These breakthroughs have led to significant progress in the development of nucleic acid-based gene drugs. The next 3-5 years will be a critical moment for the CGT industry, and the key technology to overcome the challenges is drug delivery. Those who will make huge technological breakthroughs and seize the market opportunities will be those who can make nano-delivery carriers that can accurately target and efficiently deliver nucleic acid drugs to disease tissues, and those who can cooperate deeply with major pharmaceutical multinationals.In addition, Dr. Lai looks forward to active support from the supervision authorities for the clinical development of such innovative drugs. He believes that with the efforts of pharmaceutical companies and the investment of capital, China will become a leader in the “third drug revolution” and build a gene drug ecosystem that will promote the R&amp;D of more innovative drugs and bring more good drugs to patients.

从资本助推AI技术发展的角度，和与会者共同探讨了行业发展和机遇，并分享个人经验和见解。

Discussing the industry development and opportunities with the participants from the perspective of capital boosting the development of AI technology and shared his personal experiences and i

剂泰医药赖才达博士出席2023世界人工智能大会投融资主题论坛

METiS CEO Dr. Chris Lai Attends the 2023 World Artificial Intelligence Conference Financing and Investment Sub-Forum

剂泰医药（METiS）是全球首家以人工智能驱动药物递送和药物发现的生物技术公司，集合人工智能、机器学习和量子模拟等先进技术，旨在实现更有效的创新递送材料设计、候选药物选择和制剂设计、“可编程核酸药物”开发与核酸递送设计。

核心技术

业务|Business

管线|Pipeline

剂泰医药陈红敏院士入选“全球AI药物发现专家100人”

剂泰医药赖才达博士出席2023世界人工智能大会投融资主题论坛